	US 12,128,096 B2
	Immunogenic composition
Amirreza Faridmoayer, Schlieren (CH); Rainer Follador, Schlieren (CH); Stefan Jochen Kemmler, Schlieren (CH); Michael Thomas Kowarik, Schlieren (CH); Gerald Johann Posch, Schlieren (CH); and Fabio Serventi, Schlieren (CH)
Assigned to GlaxoSmithKline Biologicals SA, Rixensart (BE)
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Filed on May 31, 2022, as Appl. No. 17/804,679.
Application 17/804,679 is a division of application No. 16/620,921, granted, now 11,376,314, previously published as PCT/EP2018/069355, filed on Jul. 17, 2018.
Claims priority of application No. 1711637 (GB), filed on Jul. 19, 2017.
Prior Publication US 2023/0060184 A1, Mar. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/09 (2006.01); A61K 39/102 (2006.01); C08B 37/00 (2006.01); A61K 35/74 (2015.01); A61K 38/00 (2006.01); A61K 47/36 (2006.01); B01J 20/32 (2006.01); C07K 9/00 (2006.01); C07K 14/315 (2006.01)

CPC A61K 39/092 (2013.01) [A61K 39/102 (2013.01); C08B 37/006 (2013.01); A61K 35/74 (2013.01); A61K 38/00 (2013.01); A61K 47/36 (2013.01); B01J 20/32 (2013.01); C07K 9/005 (2013.01); C07K 14/315 (2013.01)]

13 Claims

1. A vaccine comprising an immunogenic composition comprising an immunologically effective amount of a polysaccharide-carrier protein conjugate,

wherein the polysaccharide comprises one or more and less than 500 repeat unit(s) Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→,

wherein the polysaccharide is a hybrid oligosaccharide or polysaccharide having a structure: (B)n-A→wherein A is an oligosaccharide containing at least 2, 3, 4, 5, 6, 7 or 8 monosaccharides with a hexose monosaccharide derivative at the reducing end (indicated by the arrow in the diagram), wherein the hexose monosaccharide derivative is N-acetylglucosamine (GlcNAc), N-acetylgalactoseamine (GalNAc), 2,4-Diacetamido-2,4,6-trideoxyhexose (DATDH), N-acetylfucoseamine (FucNAc), or N-acetylquinovosamine (QuiNAc); wherein B is an oligosaccharide repeat unit >4)-B-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→; and wherein n is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or at least 20; and

wherein the immunogenic composition comprises 10 or more capsular saccharides from different S. pneumoniae serotypes conjugated to a carrier protein.